-
Mashup Score: 0Ro introduces the Ro Operating System (ro.OS) - 4 day(s) ago
/PRNewswire/ — Ro, the leading direct-to-patient healthcare company, today introduced the Ro Operating System (ro.OS) – its technology platform delivering…
Source: www.prnewswire.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 2
/PRNewswire/ — NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a company developing novel treatments for severe neurodegenerative diseases,…
Source: www.prnewswire.comCategories: General Medicine News, Rare DiseaseTweet
-
Mashup Score: 6US FDA approves Boehringer Ingelheim’s high-concentration, citrate-free formulation of Cyltezo® (adalimumab-adbm) injection - 8 day(s) ago
/PRNewswire/ — Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has approved the high-concentration, citrate-free…
Source: www.prnewswire.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 46
Study examines if gene editing can help people living with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) WASHINGTON, May 2, 2024 /PRNewswire/ — The…
Source: www.prnewswire.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 1
/PRNewswire/ — Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and PathAI, a global provider of artificial intelligence-powered…
Source: www.prnewswire.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0
/PRNewswire/ — With every successive year, the lines between medical devices and consumer electronics become increasingly blurred – medtech companies seek to…
Source: www.prnewswire.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 0Invitae Enters into Agreement with Labcorp for Sale of Business - 16 day(s) ago
/PRNewswire/ — Invitae (OTC:NVTA), a leading medical genetics company, announced that Labcorp (NYSE: LH), a global leader of innovative and comprehensive…
Source: www.prnewswire.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 33Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis - 19 day(s) ago
− Results from the Phase 3 SELECT-GCA study showed 46 percent of patients with giant cell arteritis (GCA) who were treated with upadacitinib (RINVOQ®; 15 mg)…
Source: www.prnewswire.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 0
/PRNewswire/ — With every successive year, the lines between medical devices and consumer electronics become increasingly blurred – medtech companies seek to…
Source: www.prnewswire.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 0
/PRNewswire/ — VieCure, a cancer care company, today announced that it is integrating e-prescribing and medication management solutions from health technology…
Source: www.prnewswire.comCategories: General Medicine News, General HCPsTweet
.@ro introduces the Ro Operating System (ro.OS): vertically integrates nationwide #telehealth, lab & pharmacy services powered by a proprietary suite of applications, tools, features https://t.co/qDX31bCVaM